Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2009;104:842-850
Published online before print February 19, 2009, doi: 10.1161/CIRCRESAHA.108.189837
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
104/7/842    most recent
CIRCRESAHA.108.189837v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, S.-Y.
Right arrow Articles by Lee, I.-K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, S.-Y.
Right arrow Articles by Lee, I.-K.
Related Collections
Right arrow Cardiovascular Pharmacology
Right arrow Restenosis
Right arrow Cell signalling/signal transduction
Right arrow Smooth muscle proliferation and differentiation
Right arrowRelated Article
(Circulation Research. 2009;104:842.)
© 2009 American Heart Association, Inc.


Molecular Medicine

Activation of NAD(P)H:Quinone Oxidoreductase 1 Prevents Arterial Restenosis by Suppressing Vascular Smooth Muscle Cell Proliferation

Sun-Yee Kim*, Nam Ho Jeoung*, Chang Joo Oh, Young-Keun Choi, Hyo-Jeong Lee, Han-Jong Kim, Joon-Young Kim, Jung Hwan Hwang, Surendar Tadi, Yong-Hyeon Yim, Ki-Up Lee, Keun-Gyu Park, Seung Huh, Ki-Nam Min, Kyeong-Hoon Jeong, Myoung Gyu Park, Tae Hwan Kwak, Gi Ryang Kweon, Kouichi Inukai, Minho Shong, In-Kyu Lee

From the Department of Internal Medicine (S.-Y.K., N.H.J., C.J.O., Y.-K.C., H.-J.L., H.-J.K., J.-Y.K., I.-K.L.), Department of Surgery (S.H.), Kyungpook National University School of Medicine, Daegu, South Korea; Department of Internal Medicine (J.H.H., S.T., M.S.), Department of Biochemistry (G.R.K.), Chungnam National University School of Medicine, Daejeon, South Korea; Korea Research Institute of Standard and Science (Y.-H.Y.), Daejeon, South Korea; Department of Internal Medicine (K.-U.L.), University of Ulsan College of Medicine, Seoul, South Korea; Department of Internal Medicine (K.-G.P.), Keimyung University School of Medicine, Daegu, South Korea; Mazence Inc R&D Center (K.-N.M., K.-H.J., M.G.P., T.H.K.), Suwon, South Korea; and Division of Endocrinology and Diabetes (K.I.), Department of Medicine, Saitama Medical School, Saitama, Japan.

Correspondence to In-Kyu Lee, Department of Internal Medicine, Kyungpook National University School of Medicine, 50 Samduck-2 ga, Jung-gu, Daegu, 700-721, South Korea. E-mail leei{at}knu.ac.kr

Abnormal proliferation and migration of vascular smooth muscle cells (VSMCs) are important pathogenic mechanisms in atherosclerosis and restenosis after vascular injury. In this study, we investigated the effects of β-lapachone (βL) (3,4-Dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione), which is a potent antitumor agent that stimulates NAD(P)H:quinone oxidoreductase (NQO)1 activity, on neointimal formation in animals given vascular injury and on the proliferation of VSMCs cultured in vitro. βL significantly reduced the neointimal formation induced by balloon injury. βL also dose-dependently inhibited the FCS- or platelet-derived growth factor-induced proliferation of VSMCs by inhibiting G1/S phase transition. βL increased the phosphorylation of AMP-activated protein kinase (AMPK) and acetyl-CoA carboxylase 1 in rat and human VSMCs. Chemical inhibitors of AMPK or dominant-negative AMPK blocked the βL-induced suppression of cell proliferation and the G1 cell cycle arrest, in vitro and in vivo. The activation of AMPK in VSMCs by βL is mediated by LKB1 in the presence of NQO1. Taken together, these results show that βL inhibits VSMCs proliferation via the NQO1 and LKB1-dependent activation of AMPK. These observations provide the molecular basis that pharmacological stimulation of NQO1 activity is a new therapy for the treatment of vascular restenosis and/or atherosclerosis which are caused by proliferation of VSMCs.


Key Words: vascular smooth muscle cell • β-lapachone • AMPK • NQO1 • restenosis


Related Article:

Restenosis Revisited
Patrick A. Calvert and Martin R. Bennett
Circ. Res. 2009 104: 823-825. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
Circ. Res.Home page
B. Fisslthaler and I. Fleming
Activation and Signaling by the AMP-Activated Protein Kinase in Endothelial Cells
Circ. Res., July 17, 2009; 105(2): 114 - 127.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
P. A. Calvert and M. R. Bennett
Restenosis Revisited
Circ. Res., April 10, 2009; 104(7): 823 - 825.
[Full Text] [PDF]